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Key-message:  
Cesarean hysterectomy is the gold standard treatment for placenta accreta. For placenta 
percreta with bladder invasion or for young women who want the option of future pregnancy 
and who agree to close follow-up monitoring, conservative treatment is a valid option. 
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Abstract: 
Cesarean-hysterectomy is considered the gold standard treatment for placenta accreta. In 
young women who want the option of future pregnancy and agree to close follow-up 
monitoring, conservative treatment is a valid option. Several key points of both cesarean 
hysterectomy and conservative treatment remain debatable, such as timing of delivery, 
attempted removal of the placenta, use of temporal internal iliac occlusion balloon catheters, 
ureteral stents, prophylactic embolization, and methotrexate. In cases of placenta percreta 
with bladder involvement, conservative treatment may be the optimal management. 
Regardless of the chosen option, the woman and her partner should be warned of the high risk 
of maternal complications related to an abnormally invasive placenta. 
 
Key words: abnormally invasive placenta, placenta accrete or percreta, management, 
antenatal diagnosis, cesarean hysterectomy, conservative treatment.  
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Introduction 
Abnormally invasive placentas are a life-threatening condition characterized by 
placental villi being abnormally adherent to the myometrium due to the absence of, or defects 
in, the normal decidual basalis and the fibrinous Nitabuch´s layer (1). They are commonly 
classified into three distinct grades according the degree of the placental villi invasion into the 
myometrium: placenta accreta (placental villi are attached to the decidual surface of the 
myometrium), placenta increta (placental villi more deeply invading into the myometrium) 
and placenta percreta (placental villi invade through the myometrium and the uterine serosa 
and sometimes into adjacent organs, such as the bladder) (2). In a clinical setting and daily 
practice, these histopathological differences are probably non-existent. Therefore, in this 
article, the term “placenta accreta” is used as a general term to describe all of these three 
conditions whereas the term percreta refers to placenta percreta (2). 
Placenta accreta has become an important cause of maternal morbidity and mortality. 
For example, more than half of women are transfused or admitted to an intensive care unit 
(ICU) (3-4) and mortality rates as high as 7% have been reported to be associated with 
placenta percreta (5). Moreover, placenta accreta is the leading cause of peripartum 
hysterectomy (6), failed vessel ligation (7) and pelvic arterial embolization (8). Nevertheless, 
the optimal management of placenta accreta remains a topic of debate. The aim of our review 
was to assess the available useful procedures in an attempt to contribute to decreasing the 
morbidity of this condition. 
 
Methods 
Data for this review were identified based on searches of Medline, Current Contents, and 
PubMed from 1965 to January 2012, and references from relevant articles using the following 
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search terms: “placenta accreta”, “placenta increta”, “placenta percreta”, “morbidly adherent 
placenta”, “antenatal diagnosis”, “extirpative approach”, “cesarean-hysterectomy”, 
“conservative treatment”. Only articles published in English were included. Further articles 
were identified by cross-referencing. The majority of publications on placenta accreta are 
cohort or case-control studies, or case series/reports and descriptive studies. No randomized 
controlled trials were retrieved. Articles on more general topics were selected on the basis of 
their relevance or interest as regards this specific subject with particular attention given to 
articles that dealt with the management of placenta accreta.  
 
Organization of the delivery 
Role of prenatal identification of placenta accreta 
Prenatal identification of placenta accreta is essential in order to manage optimal delivery 
circumstances for these patients (9). The key role of this in the management of patients with 
placenta accreta was highlighted by Warshak et al. (4). These authors reported that patients 
with a pre-delivery diagnosis of placenta accreta for whom a cesarean hysterectomy with no 
attempted removal of the placenta was planned at 34-35 weeks gestation, required fewer units 
of packed red blood cells and tended to have a lower estimated blood loss than those with no 
pre-delivery diagnosis (4). This decrease in maternal morbidity for patients with a pre-
delivery diagnosis of placenta accreta has also been reported by others (10).  
Another advantage of prenatal identification is the possibility to plan the delivery in a suitable 
center with a multidisciplinary team and adequate equipment and resources including a 
maternity-oriented intensive care unit (ICU), an embolization unit with interventional 
radiologists, a blood bank capable of managing massive transfusion requirements, and the 
availability of other technical skills (urologists, vascular surgeons). It makes intuitive sense 
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that expertise and experience are useful when managing difficult and somewhat uncommon 
problems. This has been demonstrated by Eller et al. who found that maternal morbidity is 
reduced in women with placenta accreta who delivered in a tertiary care hospital with a 
multidisciplinary care team in comparison with those managed in standard obstetric care 
facilities (11).  
Timing of delivery 
The optimal timing of delivery for the patients with placenta accreta remains controversial. 
Whatever the gestational age chosen, practitioners have to plan an organization to include the 
unexpected occurrence of possible cases of acute bleeding requiring an emergency cesarean 
section. In a large multicenter trial, 23.9% (27/113) of women with placenta accreta in whom 
cesarean section was planned had an emergency delivery (8). O’Brien et al. reported that after 
35 weeks, 93% of patients with placenta accreta experienced hemorrhage necessitating 
delivery (5). In order to decrease this risk of emergency delivery, Warshak et al. proposed that 
patients with a highly suspected placenta accrete should be delivered by cesarean 
hysterectomy at 34–35 weeks (4). Compared with patients with no pre-delivery diagnosis of 
placenta accreta (n=37; mean gestation at delivery 33.9±1.1 weeks), those with a pre-delivery 
diagnosis (n=62; mean gestation at delivery 34.7±1.2 weeks) demonstrated significantly 
higher rates of admission to the neonatal ICU (86% compared with 60%), and longer neonatal 
hospital stays (10.7±1.9 compared with 6.9±2.1 days). Despite the limited size of their patient 
cohort, this study suggested that higher neonatal morbidity may occur if the cesarean is 
planned before 36 weeks of gestation (4). Finally, an analytical decision model showed that 
the preferred gestational age at which to deliver these individuals at high risk is almost 
certainly at or beyond 34 weeks, but not later than 37 weeks (12). Nevertheless, it has been 
emphasized that the current literature detailing the probability of events related to emergency 
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delivery of women with suspected placenta accrete, is not definitive enough to allow the 
unequivocal establishment of a single ideal gestational age at which to deliver the women 
who are at high risk (12). Therefore, in absence of any bleeding, it seems currently reasonable 
to plan delivery at about 35-36 weeks gestation in cases of suspected placenta accreta. This 
opinion seems to be shared by the majority of American practitioners as about 50% of 
respondents reported in two national surveys to have planned the cesarean section at 36 weeks 
gestation (13,14).  
Procedures 
There are four basic options for management of placenta accreta: the extirpative method, the 
cesarean hysterectomy, conservative treatment and the one-step conservative surgery which is 
an alternative conservative technique. Whatever the option chosen, when placenta accreta is 
suspected before delivery in a woman with an anterior placenta previa, it is recommended to 
perform a vertical fundal uterine incision to avoid the placenta and reduce the risk of massive 
postpartum hemorrhage (PPH).    
  
The extirpative method  
 This procedure consists of performing a forcible manual removal of the placenta delivery in 
an attempt to obtain an empty uterus. The technique is associated with a higher rate of 
massive PPH and subsequent peripartum hysterectomy than the conservative approach (15-
16). Therefore, this option should be abandoned when other procedures are available (17). 
Unfortunately, this happens in most cases with undiagnosed placenta accrete, i.e. it is not a 
voluntary decision but rather the result of an unforeseen intraoperative complication when an 
accreta is not suspected. That concept underlines the importance of preoperative diagnosis. 
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Cesarean section hysterectomy  
This procedure consists of performing a hysterectomy after the birth of the child without 
attempting removal of the placenta when placenta accreta is strongly suspected antenatally or 
after an attempted placental removal when the diagnosis of placenta accreta is not made until 
during delivery. This option is currently recommended by the American College of Obstetrics 
and Gynecology as well as various authors, and is considered the gold standard treatment for 
placenta accreta (1, 5, 18,19, 20).The maternal mortality rate of cesarean hysterectomy seems 
to be relatively low. Among 95 deaths after 1 461 270 births between 2000 and 2006, only 
one death secondary to placenta accreta had been reported in the United States (21). 
Nevertheless, mortality rates as high as 7% have been reported to be associated with placenta 
percreta (5). Surprisingly, there are very few case series which have assessed maternal 
morbidity after cesarean hysterectomy. The most methodologically sound studies have only 
recently been published (3,4,22,23). Table 1 summarizes maternal morbidity of the largest 
reported retrospective case series of a peripartum hysterectomy for placenta accreta. One of 
the most interesting is the study of Eller et al. (3), who found, in a series of 76 cases of 
cesarean hysterectomy for placenta accreta a 42.1% transfusion rate (≥ 4 red blood cells), 
28.9% cystotomy rate, ureteral injury in 6.6% of the women, while infectious complications 
occurred in 33.3% and in all major morbidity among 59% of the women (Table 1). In spite of 
some methodological flaws (24), it appears that maternal morbidity is significantly reduced 
when no attempt is performed to remove the placenta (3). Warshak et al. (4) described 
morbidity of cesarean hysterectomy for placenta accreta at a similar level to what Eller et al. 
(3) observed. In that series of 62 cases of cesarean-hysterectomy, performed without 
attempting to remove the placenta, the average estimated blood loss, number of red blood 
cells transfused, and operative time was 2344 mL, 4.7 and 194 minutes, respectively, while 
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the rates of bladder injuries, ureteral injuries and neonatal ICU referrals were 23%, 8% and 
72%, respectively (4) (Table 1).  
The main advantage of cesarean hysterectomy (without attempted removal of the placenta) is 
probably to limit the risk of bleeding in order to reduce maternal morbidity, although this still 
remains high (3, 25). Its major drawback is the loss of fertility, which may seem particularly 
unwarranted when placenta accreta is not confirmed histologically (this was the case in 28% 
of cases of prenatal suspicion of placenta accreta in the study of Eller et al. (3)). Moreover, 
there is a lack of consensus regarding several detailed key points of the cesarean hysterectomy 
strategy: 
 Should preventive arterial embolization be performed after birth?  
This has been proposed to decrease maternal morbidity following cesarean hysterectomy. 
Nevertheless, only one limited study including a small cohort (n=26) has addressed this issue.  
Angtsmann et al. observed a significant decrease in blood loss, number of transfused patients 
and number of red blood cell units transfused in a short ambispective cohort of women who 
underwent arterial embolization before hysterectomy compared with patients who had a 
hysterectomy just after the birth of the child (21). In our practice, we do not use  prophylactic 
embolization before performing an hysterectomy. 
 Should temporal internal iliac occlusion balloon catheters be used?  
The main potential advantage of these catheters is to reduce blood loss and its inherent 
morbidity by reducing the blood flow distal to the site of occlusion, through decreasing the 
blood flow to the uterine arteries after a balloon inflation in the internal iliac arteries, as well 
as improving the visualization of the surgical field until hemostasis or hysterectomy can be 
achieved. Nevertheless, some authors have advocated that routine inflation of the balloons 
immediately following delivery of the infant may exacerbate collateral blood flow (26). It has 
been suggested that the extensive network of collateral vessels present in the gravid pelvis 
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may explain some failures of occlusive balloons, whereas collateral circulation from cervical, 
ovarian, rectal, femoral, lumbar, and sacral arteries may also contribute to the overall blood 
loss (26).  
Another advantage of the preoperative placement of hypogastric catheters is that they can be 
used for postoperative embolization should bleeding complications occur after an intended 
hysterectomy. However, owing to differences regarding the technique, protocols, 
heterogeneous sets of management and only small cases series with discordant results 
(26,27,28,29), there is currently no consensus regarding their use. In particular, the Royal 
College of Obstetricians and Gynaecologists has underlined the need of further evaluation 
before its recommendation (30). Among the only three retrospective comparative studies that 
have assessed maternal outcome following cesarean hysterectomy alone vs. placement of 
balloon catheters before performing cesarean hysterectomy (26,27,28), there were no 
differences for estimated blood loss, transfused blood products, operative time and length of 
hospitalization between patients who had balloon catheters plus hysterectomy (n=19) and 
those who had hysterectomy alone in the largest series (n=50) (26). As this procedure is 
associated with a high rate of harmful effects, it seems difficult to recommend this 
controversial procedure requiring fetal radiation in the absence of a significant decrease of 
maternal morbidity. In fact, it has been estimated that surgical complications, such as 
puncture site  hematomas, false aneurysms, dissection of femoral arteries, air in pressurized 
lines, symptomatic hypotension, and bowel or ureteral injury, and serious thromboembolic 
events, occur approximately in 6-16% and about 5% of women, respectively (29).  
 Should ureteral stents be used? 
There is no study that has specifically assessed this issue. The most interesting findings are 
provided by the study of Eller et al. (3). In this study, in cases of suspected placenta accreta, a 
preoperative ureteral stent placement was attempted in 44%of cases (25/57). The stent 
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placement was achieved on the right and left sides in only 68% (17/25) of cases, on only one 
side in 16% (4/25) of cases, and neither side in 16% (4/25). Women with preoperative 
bilateral ureteral stents had a lower incidence of early morbidity compared with women 
without stents (18% (3/17) versus 55% (22/40), p= .018). Moreover, these women had a non-
significant reduction in ureteral injury (0 vs. 7%). Therefore, this study suggests that ureteral 
stent placement may help to reduce the risk of ureteral injury (3). However, further evaluation 
is required before considering routine ureteral stents used for all women with placenta accreta. 
In recent American surveys, 26% to 35% of respondents reported using ureteral stents in 
planning for a placenta accreta case (13,14). 
   
Conservative treatment  
This option consists of delivering the child, tie and then cut the umbilical cord at its base to 
leave the placenta in place adhering either partially or totally to the myometrium, and to close 
the hysterotomy (Fig. 1). Conservative treatment can also be performed following a vaginal 
delivery when the placenta is not delivered and no plane of cleavage is found between the 
uterus and the placenta, but only if this attempt to remove the placenta was careful, without 
force or insistence. Conservative treatment avoids a hysterectomy in about 75-80% of cases 
but is associated with a risk of transfusion requirements, infection and severe maternal 
morbidity (15,16, 31,32). In addition, it requires long-term monitoring. Until recently, only a 
very limited amount of data regarding maternal outcome after conservative management was 
available, based only on case reports and short case series from individual tertiary-care 
institutions (15,16, 32).  
In order to obtain statistical power and satisfactory external validity, a French multicenter 
retrospective study was conducted to determine the maternal outcome after conservative 
treatment (31). The results of this study concerning 167 cases of placenta accreta (59% of 
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placentas were partially left in place and 41% were totally left in place) are summarized in 
Table 2 (31). They confirm the overall success rate previously published (15, 16) with uterine 
preservation (no hysterectomy) in 78.4% of cases, and severe maternal morbidity in 6% 
(10/167) (31). One maternal death related to multiorgan failure occurred in a patient with 
medullary aplasia, nephrotoxicity with acute renal failure, followed by peritonitis with septic 
shock, after the injection of methotrexate in the umbilical cord.  
An empty uterus was obtained spontaneously in 75% of cases after a median of 13.5 weeks 
(min: 4 weeks, max: 60 weeks). Hysteroscopic resection and/or curettage were performed to 
obtain an empty uterus in 25% with a median of 20 weeks (min: 2 weeks, max: 45 weeks) 
(31). In a recent American survey, 32% of providers had attempted conservative management 
for placenta accreta (13).  
Nevertheless, similarly to the cesarean hysterectomy, the precise modalities of conservative 
treatment remain to be determined:  
 Should a routine gentle attempted removal of the placenta be made in cases of suspected 
prenatal placenta accreta?  
The main advantage is not only to avoid leaving an in situ placenta, in case of false-positive 
imaging, but also to be able to remove the “non-accreta” portion when the placenta adheres 
partially to the myometrium, in order to reduce the volume left in the uterus. However, this 
attempted removal of the placenta can cause severe bleeding with the risk of maternal 
complications and hysterectomy. Our current practice is to attempt gently to remove the 
placenta only in cases of unconvincing findings of placenta accreta. An example was a 
nulliparous woman with a history of curettage in whom the ultrasonography revealed only 
intraplacental lacunae in a low-lying anterior placenta, with inconclusive findings on 
magnetic resonance imaging, as well as no evidence of placenta accreta during the cesarean.     
 Should methotrexate adjuvant treatment be administered?  
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Some authors have proposed the use of methotrexate to hasten the placental resolution (33). 
Its efficacy for this indication has never been demonstrated and only case reports and very 
short case series with no control group have been reported (34). The RCOG does not 
recommend its routine use (30). The low rate of placental cell turnover compared to what is 
observed in early pregnancy suggests a much lower efficacy of methotrexate in late compared 
to early pregnancy. In addition, methotrexate exposes the patient to the risk of neutropenia or 
medullary aplasia, even with a single dose in a young patient for the treatment of ectopic 
pregnancy (35). These types of side-effects can have a dramatic impact in a patient with an 
intrauterine placenta with a 30% risk of infectious complications (31). Finally, the only case 
of maternal death after conservative treatment was secondary to a cascade of complications 
(bone marrow suppression, sepsis, renal failure) attributed to an intra-umbilical cord 
administration of methotrexate (31). For these reasons, we do not advocate the use of 
methotrexate in cases of conservative treatment.  
 Should a preventive uterine devascularization be carried out in the absence of bleeding?  
We have only very limited data to answer this question. This preventive devascularization can 
be achieved by the usual techniques of PPH management (embolization, bilateral uterine 
artery ligation, stepwise uterine devascularization, bilateral ligation of hypogastric arteries), 
although these uterine-sparing procedures seem to be less effective in cases of placenta 
accreta (7-8). As Angstmann et al. have shown that the implementation of a preventive 
embolization before performing hysterectomy may reduce the risk of blood loss (22), it is 
possible to speculate that within the framework of conservative treatment a prophylactic 
devascularization could prevent the occurrence of secondary hemorrhage and reduce the risk 
of blood loss (36) (Fig. 2). It could also accelerate the placental resolution. In contrast, these 
devascularization techniques may have harmful effects (8, 31). In the French multicenter 
series of 167 placenta accrete cases treated conservatively, the only two cases of uterine 
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necrosis occurred in two of 62 patients who underwent arterial embolization (31). However, 
further evaluation is required to answer this issue.  
 How should patients with conservative management be monitored? 
Unfortunately, there are no data available regarding this important issue. In our practice, we u 
administer prophylactic antibiotics during five days and discharge the patient from hospital on 
the 8
th
 postoperative day. Moreover, subsequent follow-up requires usually weekly visits until 
the complete resorption of the placenta. The visits include a clinical examination (bleeding, 
temperature, pelvic pain), pelvic ultrasound (volume of retained tissue) and laboratory tests 
for infection (hemoglobin and leukocytes count, C-reactive protein, vaginal sample for 
bacteriological analysis) (31). 
 
The one step-conservative surgery 
This alternative conservative procedure has been mainly described by one author (37, 38, 39). 
It consists of resecting the invaded area together with the placenta and performing the 
reconstruction as a one-step procedure (38). The main stages of this alternative technique 
achieved through a median or transverse suprapubic incision are a) vascular disconnection of 
newly-formed vessels and the separation of invaded uterine from invaded vesical tissues; b) 
performing an upper-segmental hysterectomy; c) resection of all invaded tissue and the entire 
placenta in one piece with previous pervious local vascular control; d) use of surgical 
procedures for hemostasis; e) myometrial reconstruction in two planes and f) bladder repair if 
necessary (39). This procedure does not appear to alter the subsequent obstetrical outcome. 
Palacios-Jaraquemada has reported 45 pregnancies following a one step-procedure for 
placenta accreta. Of these, 44 were uneventful and only one was complicated by a recurrence 
of placenta accreta (38).  
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As we have a limited experience with the one-step conservative surgery (40), we find it 
difficult to reach a definite opinion regarding this technique. Nevertheless, we feel that this 
procedure may be less reproducible than a conservative treatment, in particular because 
achieving hemostasis may be very challenging for an inexperienced team.         
 
In summary, the available useful procedures in an attempt to decrease the morbidity of 
placenta accreta remain to be clearly determined by further studies. The prospective 
PACCRETA study has been launched in order to answer some of the questions raised in this 
article (9).  
 
Finally, we would like to emphasize the adverse effects related to false positive or negative 
findings with regard to a prenatal suspicion of placenta accreta using Doppler ultrasound 
and/or magnetic resonance imaging. These two imaging examinations do unfortunately not 
achieve a sufficiently high level of accuracy to detect a placenta accreta (9). The 
consequences of a false negative result are obvious, i.e. increased maternal morbidity (4, 
9,10,11)) and have been mentioned above. Similarly, caregivers should be aware that false 
positive results, which may occur in 28% of cases (3), also increase maternal morbidity. They 
may lead caregivers to perform unnecessary radical or conservative-surgical procedures and 
expose the women to their inherent complications. This includes in all cases a high level of 
anxiety and for the cesarean hysterectomy, loss of fertility and surgical injury; while for the 
conservative treatment, infection/sepsis as well as bleeding that may lead to a hysterectomy 
can result, to which can be added the long period of follow-up and anxiety. Caregivers should 
therefore pay particular attention to both false negative and positive of prenatal imaging 
examinations.  
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Cesarean hysterectomy or conservative treatment?  
There is only one small retrospective comparative study assessing the maternal outcome 
following cesarean hysterectomy (n=16) compared to conservative treatment (n=10) (41). No 
differences were observed between the two groups except for the estimated blood loss which 
was lower in the conservative treatment group (3625mL ± 2154 vs. 900mL ± 754) for a rate 
of uterine preservation of 60% (6/10) (41). Compared to cesarean hysterectomy, the main 
disadvantage of conservative treatment is the length of the management and the need for 
prolonged follow-up of several months, while the main benefit is the preservation of the 
uterus and thus fertility preservation. Fertility and subsequent obstetrical prognosis of patients 
who desire a pregnancy after conservative treatment does not appear to be altered (17). The 
main risk in case of future pregnancies seems to be the recurrence of placenta accreta 
estimated at 28.6% (95% confidence interval 11.3–52.2%) (17). Due to the small number of 
studies, a limited inclusion of patients in these studies, the inhomogeneity of patient 
characteristics and their management, and methodological flaws, it is very difficult to 
compare maternal morbidity after conservative treatment vs. cesarean hysterectomy. 
However, it is possible that severe maternal morbidity is increased in cases of conservative 
treatment because infectious complications, uterine necrosis and secondary hemorrhage 
associated to conservative treatment can be dramatic. Thus, it seems reasonable to propose in 
the present state of knowledge, a cesarean-hysterectomy if the patient has no desire for a 
future pregnancy, is at a relatively advanced reproductive age and is multiparous. 
Nevertheless, we believe that conservative management is an option for patients who are 
properly counseled and motivated, in particular, for women who want the option of a future 
pregnancy and who agree to close follow-up monitoring in centers with adequate equipment 
and resources (24, 25, 31). However, regardless of the chosen option (cesarean hysterectomy 
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or conservative treatment), the patient and her partner should be warned of the high risk of 
maternal complications related to placental disease.  
 
Placenta percreta with bladder invasion  
The bladder is the most frequently invaded adjacent organ when there is a placenta percreta 
(Fig. 3). In this condition, maternal morbidity is severe and high, with mostly urological 
complications (72.2%), including partial cystectomy (44%), bladder lacerations (26%), 
urinary fistula (13%), gross hematuria (9%), ureteral transaction (6%) and later small capacity 
bladder (4%). A maternal death occurred in 5.6% of cases (42). Pre-operative placement of a 
ureteral catheter is probably of great help to minimize ureteral complications (3). In this 
condition, it is likely that conservative treatment has a lower morbidity compared to radical 
treatment (25, 31, 43). This opinion was already shared by 69% of the members of the 
American Society of Perinatal Obstetricians in 1996 (5).  
 
Discussion 
In the case of a prenatal suspected placenta accreta, the extirpative method must now be 
abandoned. It seems reasonable to plan delivery at approximately 35-36 weeks of gestation. 
The advantages and disadvantages of cesarean hysterectomy and conservative management 
should be clearly exposed to the patient and the partner, who must be involved in deciding on 
the chosen option. Considering the present state of knowledge, it seems reasonable to propose 
a cesarean hysterectomy if the patient has no desire for a future pregnancy, is at a higher 
reproductive age and is parous. In these latter cases, preoperative ureteral stent placement as 
well as prophylactic embolization before hysterectomy may be considered in order to reduce 
maternal morbidity, whereas the benefit-harm balance is against the routine use of internal 
iliac occlusion balloon catheters. In contrast, if the patient wants the possibility of another 
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pregnancy, is young and nulliparous, conservative treatment with no adjuvant methotrexate 
therapy should be proposed. In rare cases of placenta percreta with bladder invasion, it seems 
reasonable to focus on conservative treatment. 
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Legends for Figures 
Fig. 1. Peri-operative view of a placenta percreta left in situ after the closing of the vertical 
fundal uterine incision. 
Fig. 2. Angiograms respectively before and after a prophylactic pelvic arterial embolization 
for placenta percreta of the left (a and b) and right (c and d) sides. Note the significant 
decrease of the vascularization at the end of the procedure.   
Fig. 3. Hysteroscopic view of a placenta percreta with a bladder invasion. 
